| Name | Title | Contact Details |
|---|
The Macroflux Corp. is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hoechst AG is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Imaging Endpoints (IE) is an imaging research and core laboratory that provides imaging CRO services to evaluate drug and device efficacy. We specialize in providing the industry`s leading radiology expertise and most advanced technologies through exquisite service. • LOCATIONS: Imaging Endpoints is based in Scottsdale, AZ, with offices in Waltham, MA, and Hyderabad, India as well as new offices opening soon in Basel, Switzerland; Amsterdam, the Netherlands and Shanghai, China. • AFFILIATES: We are an affiliate of HonorHealth, one of the largest healthcare systems nationally. We are also an affiliate of Scottsdale Medical Imaging, Ltd., part of the largest private radiology group in the US. • DEEP SCIENCE: Our Medical and Scientific Affairs Team includes world-class leaders in imaging science. Over 50 publications in leading journals have established us as a technology leader. IE`s experience spans hundreds of successful studies across all phases of development, including the most complex and high-profile Phase 3 trials in the industry. • EXPERT READERS: Our team includes over 100 physician readers comprised of 40 in-house radiologists and academically based expert radiologists, oncologists, surgeons and other physicians in the US. • GLOBAL SERVICES: We are one of the largest global imaging CROs in oncology. We receive/read scans in real-time from hundreds of imaging sites in over 35 countries. • SETTING NEW QUALITY STANDARDS: Our imaging Quality Management System (iQMS) is designed to exceed industry standards. All inspections by FDA and EMEA have resulted in zero observations, clearly demonstrating our leadership in quality. • EXCEPTIONAL STABILITY: IE has experienced a decade of high growth with no ownership change or executive leadership change in over five years.
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Veranova is a global leader in process development and manufacturing of active pharmaceutical ingredients (APIs), focused on specialty niches with expertise in highly regulated and complex chemistries. Veranova is headquartered in Wayne, PA and has operations in North America and Europe.